Journal of the European Academy of Dermatology and Venereology· 2026Q1
Dupilumab exposure and herpesvirus infection risk in atopic dermatitis: A claims‐based cohort study
- 0citations
- Q1SCImago
- 2026year
Short summary
This claims-based cohort study found no increased risk of herpesvirus infections in atopic dermatitis patients treated with dupilumab compared to other systemic therapies.
AI-generated from the title and abstract; the full text is not read.
Key points
- Claims-based cohort study analyzed atopic dermatitis patients treated with dupilumab.
- No increased risk of herpesvirus infections was observed with dupilumab use.
- Comparison group received other systemic therapies for atopic dermatitis.
- Data was sourced from IQVIA Solutions Japan G.K.
AI-generated from the title and abstract; the full text is not read.
Abstract
The data that support the findings of this study were obtained under a contract with IQVIA Solutions Japan G.K. and are not publicly available. Data may be available from IQVIA Solutions Japan G.K. subject to applicable permissions, contractual restrictions, and privacy or ethical considerations.
The authors' abstract, as published at the source. Journal of the European Academy of Dermatology and Venereology, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Dermatology
DermatologyMedicine